MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Inc (” MyMD” or “the Firm”), a medical stage pharmaceutical firm dedicated to extending healthy lifespan, today introduced that the first individual has been enrolled in the Firm’s Phase 2 medical test of lead candidate MYMD-1, an oral immune regulator medicine, as a therapy for postponing aging and also expanding healthy and balanced lifespan.
The primary endpoint for the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of (TNF-α), growth death aspect receptor I (TNFRI) and also IL-6. TNF-α and IL-6 are the healthy proteins in the body that cause swelling and assist activate the procedure of aging. The additional measures of the test will be the security, tolerability, and also pharmacokinetics in this populace of people.
” In a Stage 1 professional test of MYMD-1, we demonstrated the medication’s statistically significant efficiency in lowering levels of TNF-α, a key player in causing pathological aging, in the blood. The FDA has authorized TNF-α reduction as the main endpoint for our Phase 2 research study, which we believe placements us well for an effective Phase 2 result,” claimed Chris Chapman, M.D., President, Supervisor and also Chief Medical Police Officer of MyMD. “The initiation of client enrollment in this research study advances our objective to slow down the aging process, avoid loss of muscle mass cells in aging, limit frailty, and also expand healthy and balanced life-span.”
MyMD has actually mentioned that there are no FDA-approved medicines for treating aging disorders and expanding healthy and balanced life-span human beings, a market expected to be a minimum of $600 billion by 20251 according to a major investment bank. TNF-α blockers are one of the most prescribed drugs by profits, an international market of approximately $40 billion annually,2 as well as, according to Nature Aging journal,3 a slowdown in aging that would certainly boost life expectancy by one year deserves $38 trillion as well as by ten years deserves $367 trillion.
Along with aging, MYMD-1’s unique activity in regulating the immune system and also dealing with chronic swelling is being established for the treatment of autoimmune condition, including rheumatoid joint inflammation (RA), several sclerosis (MS), diabetes mellitus, and inflammatory digestive tract condition.
” We plan to begin creating protocols for a Phase 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The increasing frequency of rheumatoid joint inflammation as well as other autoimmune and also inflammatory conditions are driving demand for TNF inhibitors like MYMD-1, and our team believe our orally carried out drug with really low toxicity would be turbulent to the $60 billion market for RA if authorized by the FDA for this indication.”
Rheumatoid arthritis influences roughly 40 million individuals around the world.4.
Initially created for autoimmune illness, MYMD-1’s key purpose is to slow the aging process, protect against sarcopenia and frailty, and also expand healthy life expectancy. Because it can cross the blood-brain barrier and gain access to the main nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related conditions. Its mechanism of activity as well as effectiveness in diseases consisting of several sclerosis (MS) as well as thyroiditis have been examined with cooperations with numerous academic institutions. MYMD-1 is likewise revealing promise in pre-clinical research studies as a prospective therapy for post- COVID-19 problems and as an anti-fibrotic and also anti-proliferation healing.
MYMD-1 has shown effectiveness in pre-clinical researches in regulating the body immune system by executing as a discerning inhibitor of lump necrosis factor-alpha (TNF-α), a vehicle driver of chronic inflammation. Unlike various other treatments, MYMD-1 has actually been received these pre-clinical research studies to selectively obstruct TNF-α when it ends up being overactivated in autoimmune diseases as well as cytokine tornados, but not block it from doing its normal task of being an initial responder to any kind of regular kind of moderate infection. MYMD-1’s convenience of dental dosing is another differentiator contrasted to currently offered TNF-α blockers, all of which require shipment by shot or infusion. No authorized TNF prevention has ever been dosed by mouth. In addition, the medicine is not immunosuppressive and also has not been shown to cause the major negative effects typical with conventional treatments that treat inflammation.
Regarding MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific phase pharmaceutical firm devoted to extending healthy and balanced life-span, is concentrated on establishing 2 novel therapeutic systems that deal with the reasons for condition instead of only attending to the signs. MYMD-1 is a medication system based on a professional phase tiny molecule that controls the immune system to manage TNF-α, which drives chronic inflammation, as well as various other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase durability, and deal with autoimmune diseases as well as COVID-19- connected depression. The Company’s second medication platform, Supera-CBD, is being created to deal with chronic pain, dependency as well as epilepsy. Supera-CBD is an unique artificial derivative of cannabidiol (CBD) and also is being established to address and improve upon the swiftly growing CBD market, that includes both FDA approved medications as well as CBD products not presently controlled as medications. To learn more, see www.mymd.com.